Needham & Company LLC reissued their buy rating on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX – Free Report) in a research note published on Monday, Benzinga reports. The brokerage currently has a $12.00 price target on the biotechnology company’s stock.
BCRX has been the subject of a number of other research reports. Royal Bank of Canada reissued an outperform rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a research note on Monday, September 25th. StockNews.com started coverage on BioCryst Pharmaceuticals in a research note on Thursday, October 5th. They set a hold rating for the company. Jefferies Financial Group raised shares of BioCryst Pharmaceuticals from a hold rating to a buy rating and set a $11.00 target price on the stock in a research note on Friday, August 4th. HC Wainwright reissued a buy rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a research report on Friday, August 4th. Finally, Bank of America upgraded shares of BioCryst Pharmaceuticals from a neutral rating to a buy rating and set a $10.00 price objective on the stock in a research report on Thursday, July 13th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, BioCryst Pharmaceuticals has a consensus rating of Moderate Buy and an average price target of $13.63.
BioCryst Pharmaceuticals Stock Down 1.8 %
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the stock. Fifth Third Bancorp boosted its stake in shares of BioCryst Pharmaceuticals by 17,500.0% during the 3rd quarter. Fifth Third Bancorp now owns 3,520 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 3,500 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in BioCryst Pharmaceuticals by 96.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 4,865 shares of the biotechnology company’s stock worth $34,000 after buying an additional 2,388 shares during the period. Fairfield Bush & CO. bought a new stake in BioCryst Pharmaceuticals during the 1st quarter valued at approximately $34,000. State of Wyoming purchased a new position in shares of BioCryst Pharmaceuticals during the 4th quarter worth approximately $35,000. Finally, Advisory Services Network LLC raised its position in shares of BioCryst Pharmaceuticals by 46.3% in the 1st quarter. Advisory Services Network LLC now owns 4,740 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 1,500 shares in the last quarter. 91.46% of the stock is owned by hedge funds and other institutional investors.
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.
- Five stocks we like better than BioCryst Pharmaceuticals
- What Are Dividend Contenders? Investing in Dividend Contenders
- These 5 small-cap impact stocks are making social change
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Alphabet slays its earnings but falls on its sword with cloud
- What is a Mid Cap Stock? How to Invest
- There’s nothing artificial about NVIDIA’s relationship with AI
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.